Shane Barton Sells $1.58M of BioAge Labs Inc (BIOA) — SEC Form 4, Jul 01, 2026
Open-Market Net Sale · SEC Form 4
−$1,576,752
10b5-1 Plan
Equity position changed by -100.0%
Equity Position
0 sh
2,632 → 0
Equity Change
-100.0%
shares held after vs before
Filing Lag
1 business day
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Shane Barton CIK 0001836297 |
CAO
|
Shane Barton at BioAge Labs Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$1,576,752
More from this insider at BioAge Labs Inc
| 2026-02-19 | Award | — | View |
| 2025-03-10 | Buy | +$47,376 | View |
| 2025-02-20 | Award | — | View |
| 2024-12-20 | Award | — | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common StockF1 | 2026-06-29 | M - Exercise 10b5-1 | 9,301 A | $10.85 | +$100,916 | 11,933 | Direct |
| Common StockF1 | 2026-06-29 | M - Exercise 10b5-1 | 7,261 A | $8.39 | +$60,920 | 19,194 | Direct |
| Common StockF1 | 2026-06-29 | M - Exercise 10b5-1 | 8,958 A | $4.30 | +$38,519 | 28,152 | Direct |
| Common StockF1 | 2026-06-29 | M - Exercise 10b5-1 | 14,198 A | $4.38 | +$62,187 | 42,350 | Direct |
| Common StockF1F2 | 2026-06-29 | S - Sale 10b5-1 | 42,350 D | $25.21 | -$1,067,576 | 0 | Direct |
| Common StockF1 | 2026-06-30 | M - Exercise 10b5-1 | 4,290 A | $10.85 | +$46,547 | 4,290 | Direct |
| Common StockF1 | 2026-06-30 | M - Exercise 10b5-1 | 4,000 A | $8.39 | +$33,560 | 8,290 | Direct |
| Common StockF1 | 2026-06-30 | M - Exercise 10b5-1 | 4,065 A | $4.30 | +$17,480 | 12,355 | Direct |
| Common StockF1 | 2026-06-30 | M - Exercise 10b5-1 | 7,861 A | $4.38 | +$34,431 | 20,216 | Direct |
| Common StockF1F3 | 2026-06-30 | S - Sale 10b5-1 | 20,216 D | $25.19 | -$509,176 | 0 | Direct |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1F4 | $10.85 | 2026-06-29 | M - Exercise 10b5-1 | 9,301 D | $0.00 | 2033-09-26 | 9,301 Common Stock | Direct |
| Stock Option (Right to Buy)F1F5 | $8.39 | 2026-06-29 | M - Exercise 10b5-1 | 7,261 D | $0.00 | 2034-04-16 | 7,261 Common Stock | Direct |
| Stock Option (Right to Buy)F1F6 | $4.30 | 2026-06-29 | M - Exercise 10b5-1 | 8,958 D | $0.00 | 2034-12-17 | 8,958 Common Stock | Direct |
| Stock Option (Right to Buy)F1F7 | $4.38 | 2026-06-29 | M - Exercise 10b5-1 | 14,198 D | $0.00 | 2035-02-17 | 14,198 Common Stock | Direct |
| Stock Option (Right to Buy)F1F4 | $10.85 | 2026-06-30 | M - Exercise 10b5-1 | 4,290 D | $0.00 | 2033-09-26 | 4,290 Common Stock | Direct |
| Stock Option (Right to Buy)F1F5 | $8.39 | 2026-06-30 | M - Exercise 10b5-1 | 4,000 D | $0.00 | 2034-04-16 | 4,000 Common Stock | Direct |
| Stock Option (Right to Buy)F1F6 | $4.30 | 2026-06-30 | M - Exercise 10b5-1 | 4,065 D | $0.00 | 2034-12-17 | 4,065 Common Stock | Direct |
| Stock Option (Right to Buy)F1F7 | $4.38 | 2026-06-30 | M - Exercise 10b5-1 | 7,861 D | $0.00 | 2035-02-17 | 7,861 Common Stock | Direct |
Footnotes (7)
- F1
- The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. Show more
- F2
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Show more
- F3
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.42 per share, inclusive. Show more
- F4
- The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Show more
- F5
- The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Show more
- F6
- The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Show more
- F7
- The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Show more
Related filings at BioAge Labs Inc
Institutional Holders
13F holders · Jun 30, 2026
150
institutional managers reporting a position
Largest by reported value
- Ah Capital Management, L.L.C. $79.2M
- Black Rock, Inc. $69.8M
- Cormorant Asset Management, Lp $58.6M
5%+ Holders · 13D/G
3 filers
-
Black Rock, Inc. 5.0%
-
Kristen Fortney 7.2%
Other insiders at BioAge Labs Inc
GET /v1/forms/4/0001836297-26-000005
API docs
View Original SEC Filing